REGENXBIO Reports First Quarter 2019 Financial and Operating Results and Additional Positive Interim Phase I/IIa Trial Update for RGX-314 for the Treatment of Wet AMD

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/13/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. MSFT
9. CRM
10. CRWV

Go back to REGENXBIO Reports First Quarter 2019 Financial and Operating Results and Additional Positive Interim Phase I/IIa Trial Update for RGX-314 for the Treatment of Wet AMD

Regenxbio (RGNX) Misses Q1 EPS by 3c

May 7, 2019 5:01 PM EDT

Regenxbio (NASDAQ: RGNX) reported Q1 EPS of ($0.89), $0.03 worse than the analyst estimate of ($0.86). Revenue for the quarter came in at $884 thousand, versus $132.39 thousand reported last year.

Reports positive interim update from RGX-314 Phase I/IIa trial for wet AMD in Cohort 3 over one yearAnnounces new IND submission for RGX-314 for a Phase II trial in diabetic retinopathy; filing planned for second half 2019 Continuing subject recruitment for RGX-121 Phase I/II trial... More